These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16117152)

  • 21. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
    Bykova OV; Kuzenkova LM; Maslova OI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
    Petkau J; White R
    Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
    [No Abstract]   [Full Text] [Related]  

  • 23. [Multiple sclerosis in the year 2000: advances in the treatment with interferon beta-1b].
    Cendrowski W
    Neurol Neurochir Pol; 2001; 35(5):855-65. PubMed ID: 11873598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.
    Kamm CP; Mattle HP;
    Trials; 2009 Dec; 10():115. PubMed ID: 20003436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
    Durelli L; Barbero P; Clerico M;
    Neurology; 2006 Dec; 67(12):2264; author reply 2264-5. PubMed ID: 17190964
    [No Abstract]   [Full Text] [Related]  

  • 26. Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?
    Polman C; Schellekens H; Killestein J
    Mult Scler; 2006 Jun; 12(3):245-6. PubMed ID: 16764335
    [No Abstract]   [Full Text] [Related]  

  • 27. Multiple lessons for multiple sclerosis.
    Hauser SL
    N Engl J Med; 2008 Oct; 359(17):1838-41. PubMed ID: 18946071
    [No Abstract]   [Full Text] [Related]  

  • 28. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
    Reder AT; Ebers GC; Traboulsee A; Li D; Langdon D; Goodin DS; Bogumil T; Beckmann K; Konieczny A;
    Neurology; 2010 Jun; 74(23):1877-85. PubMed ID: 20530324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of multiple sclerosis with human beta interferon.
    Goodin DS
    Int MS J; 2005 Nov; 12(3):96-108. PubMed ID: 16417818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guideline for the use of beta-interferons in patients with multiple sclerosis--a South African proposal.
    Multiple Sclerosis Advisory Committee of the Neurological Association of South Africa (NASA)
    S Afr Med J; 2004 Nov; 94(11):917-21. PubMed ID: 15587456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon β-1a for multiple sclerosis: old drug, new clothes.
    Hartung HP
    Lancet Neurol; 2014 Jul; 13(7):638-9. PubMed ID: 24878062
    [No Abstract]   [Full Text] [Related]  

  • 32. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of relapsing-remitting multiple sclerosis with recombinant interferon-beta preparations].
    Mäurer M; Gold R; Toyka KV; Rieckmann P
    Nervenarzt; 2001 Feb; 72(2):108-16. PubMed ID: 11256144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Beta interferon and thyroid].
    Laaribi O; Marrakchi A; Msyah L; Hafidi A
    Ann Endocrinol (Paris); 2006 Mar; 67(1):42-4. PubMed ID: 16596057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study.
    Doerner M; Beckmann K; Knappertz V; Kappos L; Hartung HP; Filippi M; O'Connor PW; Arnason B; Cook S; Jeffery D; Comi G; Limmroth V
    Eur Neurol; 2014; 71(3-4):173-9. PubMed ID: 24457374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Emerging new therapies for relapsing remitting multiple sclerosis].
    Anis S; Achiron A
    Harefuah; 2014 Nov; 153(11):658-62, 687, 686. PubMed ID: 25563027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Optimized compliance].
    Krankenpfl J; 2005; 43(7-10):238. PubMed ID: 16515308
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis].
    Sørensen S; Koch-Henriksen NJ; Pedersen CR; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E;
    Ugeskr Laeger; 2004 Oct; 166(41):3606-9. PubMed ID: 15515467
    [No Abstract]   [Full Text] [Related]  

  • 39. [Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal].
    Khabirov FA; Babicheva NN; Khaĭbullin TI; Aver'ianova LA; Granatov EV; Akhmedova GM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9 Pt 2):113-22. PubMed ID: 23235429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Results of a multicenter study of Rebif-22 mcg administration in Russia].
    Zavalishin IA; Gusev EI; Iakhno NN; Skoromets AA; Boĭko AN; Demina TL; Burlutskiĭ A P ; Beĭn BN; Sholomov II; Pereserdova AV; Stoĭda NI; Zakharova MN; Adarcheva LS; Niiazbekova AS; Askarova LSh; Oleĭnikov VG; Rebrova OIu; Shmidt TE; Davydovskaia MV; Totolian NA; Beskhmel'nitsina IA; Bragina OV; Ponomareva GL; Durseneva OM; Voronchikhina SA; Volkova LI; Turova EL; Streknev AG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):73-8. PubMed ID: 12938639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.